-+ 0.00%
-+ 0.00%
-+ 0.00%

Will DISCO Cancer Deal Change AbbVie (ABBV) Narrative

Simply Wall St·11/20/2026 23:14:17
Listen to the news
  • AbbVie and DISCO Pharmaceuticals recently announced a collaboration worth up to US$2.5b to develop bispecific cancer therapies for solid tumors, combining DISCO’s DISCOtech platform with AbbVie’s oncology research and potential licensing options.
  • The deal adds a targeted solid tumor program alongside AbbVie’s established immunology and neuroscience franchises, with milestone and royalty structures that closely tie R&D spend to clinical and commercial progress.
  • We will look at how AbbVie’s concentrated growth story intersects with this DISCO bispecific oncology deal and its pipeline implications.

Compare AbbVie’s oncology push with other potential breakouts by scanning our hand-picked list of 42 high quality undervalued stocks that pair cash generation with balance sheet strength.

AbbVie Investment Narrative Recap

To own AbbVie, you need to be comfortable with a story that still leans heavily on Skyrizi and Rinvoq while using deals like DISCO to deepen the next layer of oncology and immunology. According to IamPotato, an investor in the Simply Wall St Community, the firm has largely finished the Humira handoff and now depends far more on those two newer drugs.

Right now, the key near term catalyst is whether immunology and neuroscience keep carrying overall revenue as older oncology assets face pressure. The biggest risk is that concentration in a few products meets pricing headwinds or slower uptake. Recent ETF selling and Citadel’s position cuts look more like flow than a change in AbbVie’s operating picture.

The DISCO collaboration is the most relevant fresh development for this setup because it directly tackles the gap that IamPotato flagged in oncology. AbbVie is tying R&D spending to milestones and potential licensing, so the economic outlay is linked more tightly to clinical progress instead of simply raising internal trial budgets.

For you, the practical question is execution. If AbbVie can move at least one of these bispecific solid tumor assets into meaningful late stage trials, it adds another potential lever alongside immunology and neuroscience. If the programs stall, investors may revisit the same concentration risk and balance sheet issues such as high debt and negative equity.

On those figures, IamPotato’s narrative lands on a fair value of US$310.00 for AbbVie, using 9.1% annual revenue growth and a future profit margin of 15.6% to describe what they see as a balanced outcome between concentration risk and the current immunology and neuroscience strength.

Explore how AbbVie's fair value highlights an 8% potential upside to its current price before other investors close that gap.

NYSE:ABBV 1-Year Stock Price Chart
NYSE:ABBV 1-Year Stock Price Chart

Exploring Other Perspectives

Three fair value estimates from the Simply Wall St Community span roughly US$316 to US$421, so some members see AbbVie as close to fully priced while others model far more upside. You are weighing those pre news views against ETF selling, Citadel’s cut and fresh oncology deal headlines. Opinions clearly diverge. Explore the full spread before forming your own stance.

Explore 2 other AbbVie fair value estimates, including one that suggests there could be as much as 47% upside from the current price!

Decide For Yourself

Don't just follow the ticker; dig into the data and build a conviction that's truly your own.

Looking for more AbbVie investment ideas?

If this AbbVie story has sharpened your view on risk, return and concentration, use that same lens to size up other opportunities with the Simply Wall St Screener.

  • Prefer mature businesses with room to rerate on quality and valuation, rather than hoping for a turnaround? Then scan our curated set of 42 high quality undervalued stocks for ideas that might fit that brief.
  • If capital preservation matters just as much as upside, filter for companies that aim to keep volatility and financial stress in check by starting with our 31 resilient stocks with low risk scores.
  • For investors hunting for strong fundamentals beyond the usual watchlists, broaden your opportunity set by reviewing a 18 high quality undiscovered gems that could deserve a closer look.